Trial Profile
A prospective, randomized, two arm, single blind, parallel, active controlled, multicentre, phase II/III clinical study to evaluate the immunogenicity and safety of Inactivated Tetravalent Influenza vaccine (split virion) of M/s Cadila Healthcare Limited compared to marketed Inactivated Trivalent Influenza vaccine in healthy adults
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 12 Nov 2019
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine-Cadila (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Therapeutic Use
- Sponsors Zydus Lifesciences
- 12 Sep 2016 New trial record